April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Adjuvant Nivolumab Misses DFS End Point in Locally Advanced High-Risk RCC
January 27th 2024Treatment with nivolumab did not reach the primary endpoint of disease-free survival when compared with placebo in patients with localized renal cell carcinoma at high risk of relapse after nephrectomy in the phase 3 CheckMate 914 trial.
The Role of Registered Nurses in the Multidisciplinary Treatment of Advanced RCC
December 14th 2023Nurses play a key role in kidney cancer care by educating patients on medications, closely monitoring and managing side effects, coordinating care, providing emotional support, and serving as the first line of communication with patients about treatment concerns.
Diagnosis and Risk Stratification of Patients With RCC
November 30th 2023Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.
Patient Scenario 2: Second-Line Treatment Options in Clear-Cell RCC
November 20th 2023Reviewing the case of a case of a 73-year-old man with metastatic clear cell kidney cancer, experts discuss second-line treatment options informed by prior treatment response, patient goals, and adverse event profiles.
Clear-Cell RCC: Impact of Risk Stratification and NCCN Guidelines on 1L Therapy
November 13th 2023Key opinion leaders reflect on treatment approaches for renal cell carcinoma in light of factors like risk classification, symptom severity, and patient preferences, with considerations ranging from active surveillance to systemic combination therapies.
Patient Scenario 1: Diagnosis and Risk Stratification of Clear-Cell RCC
November 6th 2023Join Wenxin (Vincent) Xu, MD, and his team at Dana-Farber Cancer Institute as they explore strategies for diagnosing and stratifying renal cell carcinoma, reviewing a clinical scenarios and best practices in workup.